Gapping up
In reaction to strong earnings/guidance: WDAY +10.3% (also upgraded to Outperform at Robert W. Baird), PANW +9%, PWRD +7.1%, TIF +6.8%, LDK +3.5%, NPD +3.4%, DSW +1.7%, MOV +1.2%, PLL +0.3%.
M&A news: JOSB +10.7% and MW +6% (Men's Wearhouse proposes to acquire Jos. A. Bank for $55 per share in cash), ITW +0.6% (PE firms BX, CG, APO may be bidding for ITW's packaging segment, according to reports).
Select financial related names showing strength: PBR +-3%, NBG +2.1%, ING +1.3%, BCS +1.2%, CS +1%, UBS +0.9%,
Select biotech stocks seeing continued strength: ARIA +7.2%, APPY +4.7%, OREX +2.4%.
Other news: HBIO +10.2% (still checking), BLRX +8.1% (announces new positive results in phase 2a trial for orally available inflammatory bowel disease treatment; new results show BL-7040 to reduce pro-inflammatory cytokine levels and improve colon histology in IBD patients), MACK +7.6% (MM-121 demonstrates positive signal in two Phase 2 ER/PR+ Breast Cancer Studies; Metastatic Breast Cancer Study Reinforces Biomarker Findings From Previously Reported MM-121 Study in Ovarian Cancer; Merrimack Pharma and Actavis (ACT) announce nanotechnology collaboration), BIOF +6.1% (issues statement in announced sale of plants), UNXL +4.5% (addresses market speculation), OLED +4.1% (Universal Display and Philips Technologie GmbH Announce Collaboration and Evaluation Agreement for OLED Lighting), QCOM +3.5% (finalizes sale of Omnitracs to Vista Equity Partners; will result in an estimated $0.22 to $0.25 per share gain in Q1), LGND +3.2% ( LGND to replace SHFL in the S&P SmallCap 600), CSTM +3% (still checking), RYAAY +2.2% (still checking), TTS +2.1% ( S.A.C. Capital discloses 5.0% passive stake in 13G filing), VJET +2.1% (still checking), EGY +1.7% (CEO bought 33.6K shares at $6.05 on 11/22, worth ~$200K), JONE +1.7% (to acquire assets in the Andarko Basin for $195 mln), JKS +1.6% (following LDK results), AXE +1.5% ( declares special dividend of $5.00 per common share), AG +1.3% (still checking), JCP +1.2% (J. C. Penney CEO Ullman buys 112K shares at $8.95), FFIV +1.2% (following positive mention on MadMoney and Board authorized an additional $300 mln for the co's common stock share repurchase program), MU +0.3% (Greenlight Capital discloses new position in MU as of 9/30 - amended 13F filing ), .
Analyst comments: GALE +5.2% (initiated with an Outperform at Oppenheimer), HUN +2.3% ( upgraded to Buy from Neutral at Goldman), INN +1.4% (upgraded to Outperform from Market Perform at BMO), ASML +1% (upgraded to Buy from Hold at Societe Generale), BTU +0.7% (upgraded to Outperform from Neutral at Macquarie), ALV +0.5% ( upgraded to Neutral from Sell at Citigroup ), PSEC +0.4% ( initiated with an Outperform at BMO Capital Mkts), FEYE +0.4% (upgraded to Overweight from Equal Weight at Barclays), DHR +0.4% (upgraded to Buy from Neutral at Goldman), FRX +0.3% (upgraded to Neutral from Underweight at Piper Jaffray ), MO +0.3% (initiated with a Outperform at RBC Capital Mkts)